Guggenheim Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its price target raised by research analysts at Guggenheim from $122.00 to $140.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 14.46% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Citigroup increased their price objective on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday. TD Cowen upped their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. Scotiabank lifted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a research note on Thursday, December 4th. Bank of America boosted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Wall Street Zen raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Hold” and an average target price of $119.53.

Merck & Co., Inc. Trading Up 2.1%

Shares of Merck & Co., Inc. stock traded up $2.57 during trading hours on Friday, hitting $122.32. The company’s stock had a trading volume of 2,410,233 shares, compared to its average volume of 13,752,612. The company has a market capitalization of $303.60 billion, a PE ratio of 16.81, a price-to-earnings-growth ratio of 2.00 and a beta of 0.28. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.66 and a quick ratio of 1.44. The stock has a 50 day moving average of $106.23 and a 200 day moving average of $92.85. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $122.43.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 45.22% and a net margin of 28.08%.The business had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. During the same period in the previous year, the firm earned $1.72 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Merck & Co., Inc. by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after acquiring an additional 2,185,853 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Merck & Co., Inc. by 9.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock worth $4,263,991,000 after purchasing an additional 4,636,183 shares during the period. DLD Asset Management LP lifted its holdings in Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Norges Bank bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at $2,858,570,000. Finally, Franklin Resources Inc. grew its holdings in Merck & Co., Inc. by 23.5% in the 2nd quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock valued at $2,139,901,000 after buying an additional 5,135,748 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.